Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Vanrx Pharmasystems...

    Vanrx Pharmasystems appoints Shreedhar Instruments as its distributor in India

    Written by Ruby Khatun Khatun Published On 2017-06-03T09:50:30+05:30  |  Updated On 3 Jun 2017 9:50 AM IST
    Vanrx Pharmasystems appoints Shreedhar Instruments as its distributor in India

    VANCOUVER, British Columbia: Vanrx Pharmasystems, a manufacturer of advanced aseptic filling systems for the pharmaceutical industry, has announced that Shreedhar Instruments has become its exclusive distributor in India.


    "India's pharmaceutical sector will grow to its greatest potential by using flexible manufacturing technologies that enhance competitiveness. Indian companies are investing in biosimilars and complex injectables. Vanrx was created by biotech experts to design a new type of production system, called an Aseptic Filling Workcell. Companies using their systems move injectable drugs to market faster," said Shreedhar Joshi, Managing Partner of Shreedhar Instruments.


    "Vanrx's systems are an excellent fit for drug companies who want to make complex, high-value sterile injectables. This system provides excellent compliance levels and reduces key areas of risk, thereby providing a perfect machine for exporting into the U.S., Europe and similar regulatory markets," he adds.


    "Shreedhar Instruments came highly recommended, and they already do business with many of the leading Indian pharmaceutical companies. Their sales and service teams are well-trained, and will provide excellent service to our existing and future customers. India is an important market for Vanrx and we look forward to a strong relationship," said Greg Speakman, vice president, sales and marketing for Vanrx.


    Based in Vadodara, and with offices in Ahmedabad, Mumbai, Hyderabad, and Pune, and sales and service teams in Bengaluru, Chandigarh, Goa, Surat and Vapi, Shreedhar Instruments covers all of India's major pharmaceutical manufacturing centers.


    The SA25 Aseptic Filling Workcell uses robotics to perform all material handling, filling and container closing activities. It was designed by pharmaceutical veterans who wanted to solve long-standing aseptic processing problems within conventional fill-finish systems. Their goal was to make the production of complex injectable drug products easier and improve patient safety.


    Key benefits of the SA25 Workcell include:




    • Lowers costs by using less space, fewer utilities and less operators than conventional systems.

    • Flexibility to fill and close vials, syringes or cartridges with industry-leading quality.

    • Efficient production of multiple products through fast changeover and batch cycling times.

    • Shortens time to construct filling operations or add capacity through a standardized design.

    • Scale production through additional Workcells to support flexible manufacturing capacity.

    advanced aseptic filling systemsAseptic Filling WorkcellbiosimilarsdistributorGreg SpeakmaninjectablesSA25 Aseptic Filling WorkcellShreedhar InstrumentsShreedhar JoshiVanrx Pharmasystems
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok